Evidence map›Paper›PMID 32717243›Full record

ArticleUrology2020

Increased Bacillus Calmette-Guérin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non-Muscle-invasive Bladder Cancer in United States Clinical Practice.

Kyle A Richards, Shih-Wen Lin, Ching-Yi Chuo, Christina L Derleth, Jingbo Yi, Marko Zivkovic, Sarika Ogale, Sandip Prasad, G Joel Decastro, Gary D Steinberg

Abstract read
PubMed Publisher
In one paragraph

Article in Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Kyle A RichardsUniversity of Wisconsin-Madison, Madison, WI. Electronic address: richardsk@urology.wisc.edu.
Shih-Wen LinGenentech, Inc., South San Francisco, CA.
Ching-Yi ChuoGenentech, Inc., South San Francisco, CA.
Christina L DerlethGenentech, Inc., South San Francisco, CA.
Jingbo YiGenesis Research, Hoboken, NJ.
Marko ZivkovicGenesis Research, Hoboken, NJ.
Sarika OgaleGenentech, Inc., South San Francisco, CA.
Sandip PrasadGarden State Urology, Whippany, NJ.
G Joel DecastroColumbia University Medical Center, New York, NY.
Gary D SteinbergNew York University Langone Health, New York, NY.
Genesis Medical Center · USColumbia University Irving Medical Center · USNYU Langone Health · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo characterize Bacillus Calmette-Guérin (BCG) treatment patterns and associated outcomes in a large cohort of patients with non-muscle-invasive bladder cancer (NMIBC).

methodsOur retrospective analysis of patients aged ≥66 years with stage 0-1 urothelial bladder carcinoma diagnosed between 2000 and 2012 in the United States Surveillance, Epidemiology, and End Results-Medicare database estimated proxies for recurrence and secondary events and both all-cause and bladder cancer-specific mortality. Proportional hazards models were used in conditional landmark analyses to compare adequate (≥5 induction instillations and ≥2 maintenance instillations) and inadequate BCG, stratified by National Comprehensive Cancer Network risk group.

resultsOf 39,532 patients who met the selection criteria, 16,225 (41.0%) received BCG; of them, 4602 (28.4%; 11.6% overall) received adequate treatment. Adequately treated patients were slightly younger and healthier than inadequately treated patients. Half of patients with intermediate- and high-risk NMIBC did not receive BCG; few received adequate treatment. At the 12-month landmark, adequate BCG treatment was associated with decreased risks of recurrence and of cancer-specific and all-cause mortality in patients with intermediate- and high-risk disease.

conclusionWe observed lower than expected use of adequate BCG treatment in patients with intermediate- to high-risk NMIBC despite evidence of improved outcomes, which suggested that practice patterns may not be in line with management recommendations in this population.

Indexed as

Administration, IntravesicalAgedAged, 80 and overAge FactorsBCG VaccineCarcinoma, Transitional CellDrug Administration ScheduleFemaleHumansMaleNeoplasm Recurrence, LocalPractice Patterns, Physicians'Retrospective StudiesRisk FactorsUnited StatesUrinary BladderBCG Vaccine

Identifiers

PMID32717243
OpenAlexW3044705077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.